7081-38-1

7081-38-1 structure
7081-38-1 structure
  • Name: Oxyphenbutazone monohydrate
  • Chemical Name: oxyphenbutazone hydrate
  • CAS Number: 7081-38-1
  • Molecular Formula: C19H22N2O4
  • Molecular Weight: 342.38900
  • Catalog: API Antipyretic analgesics Antipyretic and analgesic
  • Create Date: 2018-08-12 18:24:30
  • Modify Date: 2024-01-02 16:28:32
  • Oxyphenbutazone monohydrate is a Phenylbutazone (HY-B0230) metabolite, with anti-inflammatory effect. Oxyphenbutazone monohydrate is an orally active non-selective COX inhibitor. Oxyphenbutazone monohydrate selectively kills non-replicating Mycobaterium tuberculosis[1][2].

Name oxyphenbutazone hydrate
Synonyms oxyphenbutazon monohydrate
OXYPHENBUTAZONE HYDRATE
OXYPHENBUTAZONE MONOHYDRATE
OXYPHENYL BUTAZONE MONOHYDRATE
Unii-H806S4B3ns
Description Oxyphenbutazone monohydrate is a Phenylbutazone (HY-B0230) metabolite, with anti-inflammatory effect. Oxyphenbutazone monohydrate is an orally active non-selective COX inhibitor. Oxyphenbutazone monohydrate selectively kills non-replicating Mycobaterium tuberculosis[1][2].
Related Catalog
Target

COX, Bacteria[1][2]

In Vitro Oxyphenbutazone enhances the anticancer efficiency of Methotrexate (MTX) (HY-14519) in Hep3B cells[1]. Oxyphenbutazone (2.5-7.5 µM; 48 hours) co-treatment with (MTX, 0.25-1.0 µM) shows potential cytotoxicity against Hep3B cells[1]. Oxyphenbutazone exhibits reparative effects in the hepatocytes[1]. Cell Viability Assay[1] Cell Line: Hep3B cells Concentration: 2.5 µM, 5 µM, 7.5 µM Incubation Time: 48 hours Result: Enhanced the cytotoxicity of MTX.
In Vivo Oxyphenbutazone (70 mg/kg/week; p.o.; in two divided doses; for 13 weeks) exerts potential anticancer activity when co-treatment with MTX (5.0 or 2.5 mg/kg/week; i.p.)[1]. Animal Model: Wistar strain albino male rats (5-6 weeks; 150-220 g)[1] Dosage: 70 mg/kg/week (co-treatment with MTX 5.0 or 2.5 mg/kg/week) Administration: PO; once a week; in two divided doses; for 13 weeks Result: Exerted potential anticancer activity in rats when co-treatment with MTX.
References

[1]. Saleem S, et al. Oxyphenbutazone promotes cytotoxicity in rats and Hep3B cellsvia suppression of PGE2 and deactivation of Wnt/β-catenin signaling pathway. Mol Cell Biochem. 2018 Jul;444(1-2):187-196.

[2]. Gold B, et al. Nonsteroidal anti-inflammatory drug sensitizes Mycobacterium tuberculosis to endogenous and exogenous antimicrobials. Proc Natl Acad Sci U S A. 2012 Oct 2;109(40):16004-11.

Boiling Point 485.6ºC at 760 mmHg
Melting Point 96°; mp 124-125°
Molecular Formula C19H22N2O4
Molecular Weight 342.38900
Flash Point 247.5ºC
Exact Mass 342.15800
PSA 70.08000
LogP 3.55910
Storage condition 2-8°C
Version 1.2
Regulation (EC) No 1907/2006

1 - Product and Company Information

Product NameOXYPHENBUTAZONE HYDRATE

2 - Hazards Identification

SPECIAL INDICATION OF HAZARDS TO HUMANS AND THE ENVIRONMENT
Harmful if swallowed. Irritating to eyes and skin. Limited
evidence of a carcinogenic effect. May cause sensitization by
inhalation and skin contact.

3 - Composition/Information on Ingredients

Product NameCAS #EC noAnnex I
Index Number
OXYPHENBUTAZONE HYDRATE7081-38-1 NoneNone
FormulaC19H20N2O3
Molecular Weight 324,4000 AMU

4 - First Aid Measures

AFTER INHALATION
If inhaled, remove to fresh air. If not breathing give
artificial respiration. If breathing is difficult, give oxygen.
AFTER INGESTION
If swallowed, wash out mouth with water provided person is
conscious. Call a physician.

5 - Fire Fighting Measures

EXTINGUISHING MEDIA
Suitable: Water spray. Appropriate foam.
SPECIAL PROTECTIVE EQUIPMENT FOR FIREFIGHTERS
Wear self-contained breathing apparatus and protective clothing
to prevent contact with skin and eyes.

6 - Accidental Release Measures
SIGMAwww.molbase.com

PROCEDURE(S) OF PERSONAL PRECAUTION(S)
Wear self-contained breathing apparatus, rubber boots, and heavy
rubber gloves.
METHODS FOR CLEANING UP
Sweep up, place in a bag and hold for waste disposal. Avoid
raising dust. Ventilate area and wash spill site after material
pickup is complete.

7 - Handling and Storage

HANDLING
Directions for Safe Handling: Do not breathe dust. Do not get in
eyes, on skin, on clothing. Avoid prolonged or repeated exposure.
STORAGE
Conditions of Storage: Keep tightly closed. Store in a cool dry
place.
Store at 2-8°C

8 - Exposure Controls / Personal Protection

ENGINEERING CONTROLS
Safety shower and eye bath. Mechanical exhaust required.
GENERAL HYGIENE MEASURES
Wash thoroughly after handling. Wash contaminated clothing before
reuse.
PERSONAL PROTECTIVE EQUIPMENT
Special Protective Measures: Wear appropriate government approved
respirator, chemical-resistant gloves, safety goggles, other
protective clothing.

9 - Physical and Chemical Properties

AppearancePhysical State: Solid
PropertyValueAt Temperature or Pressure
pHN/A
BP/BP RangeN/A
MP/MP RangeN/A
Flash PointN/A
FlammabilityN/A
Autoignition TempN/A
Oxidizing PropertiesN/A
Explosive PropertiesN/A
Explosion LimitsN/A
Vapor PressureN/A
Partition CoefficientN/A
ViscosityN/A
Vapor DensityN/A
Saturated Vapor Conc.N/A
Evaporation RateN/A
Bulk DensityN/A
Decomposition Temp.N/A
Solvent ContentN/A
Water ContentN/A
SIGMAwww.molbase.com
Surface TensionN/A
ConductivityN/A
Miscellaneous DataN/A
SolubilityN/A

10 - Stability and Reactivity

STABILITY
Stable: Stable.
HAZARDOUS DECOMPOSITION PRODUCTS
Hazardous Decomposition Products: Carbon monoxide, carbon dioxide,
and nitrogen oxides.
HAZARDOUS POLYMERIZATION
Hazardous Polymerization: Will not occur

11 - Toxicological Information

SENSITIZATION
Sensitization: May cause allergic reaction.
SIGNS AND SYMPTOMS OF EXPOSURE
To the best of our knowledge, the chemical, physical, and
toxicological properties have not been thoroughly investigated.
Fever, sore throat, lesions in the mouth, symptoms of anemia,
unusual bleeding or bruising, dyspepsia, epigastric pain, black
or tarry stools or other evidence of intestinal ulceration, skin
rashes, significant weight gain, edema, optic neuritis,
superficial ulceration of the cornea, conjunctivitis, blurred
vision, retinal hemorrhage, toxic amblyopia, retina detachment,
agranulocytosis, aplastic anemia, liver and kidney damage.
Stomach pains, vomiting, diarrhea. Exposure can cause:
ROUTE OF EXPOSURE
Skin Absorption: May be harmful if absorbed through the skin.
Inhalation: May be harmful if inhaled. Material may be
irritating to mucous membranes and upper respiratory tract.
Ingestion: Harmful if swallowed.
Multiple Routes: Causes eye and skin irritation.
TARGET ORGAN INFORMATION
Thyroid. Liver. Kidneys. Bone marrow. G.I. System. Blood.

12 - Ecological Information

No data available.

13 - Disposal Considerations

SUBSTANCE DISPOSAL
Dissolve or mix the material with a combustible solvent and burn
in a chemical incinerator equipped with an afterburner and
scrubber. Observe all federal, state, and local environmental
regulations.

14 - Transport Information

RID/ADR
Non-hazardous for road transport.
SIGMAwww.molbase.com
IMDG
Non-hazardous for sea transport.
IATA
Non-hazardous for air transport.

15 - Regulatory Information

CLASSIFICATION AND LABELING ACCORDING TO EU DIRECTIVES
INDICATION OF DANGER: Xn
Harmful.
R-PHRASES: 22-36/38-40-42/43
Harmful if swallowed. Irritating to eyes and skin. Limited
evidence of a carcinogenic effect. May cause sensitization by
inhalation and skin contact.
S-PHRASES: 22-26-36
Do not breathe dust. In case of contact with eyes, rinse
immediately with plenty of water and seek medical advice. Wear
suitable protective clothing.
Caution: Substance not yet fully tested (EU).
COUNTRY SPECIFIC INFORMATION
Germany
WGK: 3
Self-Classification

16 - Other Information

DISCLAIMER
For R&D or manufacturing use. Not for prescription compound or
other uses.
SIGMAwww.molbase.com


SECTION 16 - ADDITIONAL INFORMATION
N/A
Hazard Codes Xn
Risk Phrases 22-36/38-40-42/43
Safety Phrases 22-26-36